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Abstract: Data are presented from two randomized, double-blind, placebo-controlled studies 
in which the tolerability of tiotropium Respimat® Soft Mist™ Inhaler (SMI), a new-generation, 
propellant-free device for use in COPD, and the ocular safety of tiotropium were examined. In 
Study 1, 36 healthy males received tiotropium 8, 16, or 32 μg (n = 9/dose) or placebo (n = 3/dose 
level), administered once daily via Respimat® SMI for 14 days. Safety and pharmacokinetics 
were evaluated. In Study 2, 48 healthy males received tiotropium 0.02, 0.04, 0.08, 0.16, 0.28, or 
0.40 μg (n = 6/dose) or placebo (n = 2/dose level), applied as two drops to one eye (the highest 
dose was a signiﬁ  cant multiple of a percentage of the proposed Respimat® SMI clinical dose that 
could be inadvertently deposited in the eye). Ocular parameters were measured over 24 hours. 
Tiotropium Respimat® SMI at doses up to 32 μg was well tolerated in Study 1; typical dose-
dependent anticholinergic adverse events of mild-to-moderate intensity were observed. In 
Study 2, ocular tiotropium administration did not affect pupil diameter, pupillary reﬂ  ex, intra-
ocular pressure, or accommodation. Tiotropium Respimat® SMI was well tolerated. Inadvertent 
ocular exposure to tiotropium up to 0.40 μg is unlikely to result in ocular adverse effects.
Keywords: Respimat® Soft Mist™ Inhaler, tiotropium, anticholinergic, chronic obstructive 
pulmonary disease
Introduction
Inhalation is well established as an effective means of delivering respiratory drugs to 
the lung. There are currently several inhalation systems available, including pressurized 
metered-dose inhalers (pMDIs) and dry-powder inhalers (DPIs). However, some pro-
pellants and leachables in these inhalers can pose a risk when used in the long term 
(Markovic 2007). The adverse event proﬁ  le associated with the inhaled drug should 
also be taken into consideration when choosing the right inhaler and the correct dose 
for a patient. For example, inhaled corticosteroids are known to increase oropharyngeal 
candidiasis and hoarseness (Yang et al 2007), and combined corticosteroid-long-acting
β-agonist inhalers can be associated with pneumonia (Nannini et al 2007). For a 
chronic disease, it is therefore important to ﬁ  nd inhaler-drug combinations that are 
not only effective, but contain safer propellants, and have the potential for minimal 
drug-related adverse events (ie, dose reduction).
The Respimat® Soft Mist™ Inhaler (SMI) was designed to address many of these 
issues. The development has been described in detail elsewhere (Zierenberg 1999). 
In short, it is a propellant-free device that uses a mechanical spring to generate a 
ﬁ  ne aerosol (the majority of the particle mass is in the region of 1−5 μm), which International Journal of COPD 2008:3(3) 398
Feifel et al
facilitates better deposition of drug in the lung compared 
with pMDIs and DPIs (Dalby et al 2004; Zierenberg 1999). 
Primarily, Respimat® SMI has been developed for use with 
the long-acting anticholinergic tiotropium, which is normally 
delivered via a DPI (HandiHaler®) (usual dose is 18 μg). The 
efﬁ  cacy, safety and pharmacokinetics of tiotropium 18 μg 
HandiHaler® are well established (Casaburi et al 2002; 
Brusasco et al 2003; Vincken et al 2002; O’Donnell et al 
2004; Niewoehner et al 2005; Kesten et al 2006). Recently 
published studies with tiotropium Respimat® SMI have 
shown that lower doses (5 μg and 10 μg) are comparable 
with tiotropium 18 μg HandiHaler® (Caillaud et al 2007), and 
superior to ipratropium 36 μg pMDI (Voshaar et al 2008). 
However, as Respimat® SMI is a novel device with improved 
lung deposition, it is important to investigate the tolerability 
of a range of tiotropium doses delivered via this device.
The ﬁ  rst aim of this paper was to examine the safety, 
tolerability and pharmacokinetics of tiotropium (8−32 μg) 
administered via Respimat® SMI to healthy male subjects 
(Study 1). The dose-range used was based on ﬁ  ndings from 
an earlier multiple-dose study performed with HandiHaler® 
(Boehringer Ingelheim data on ﬁ  le), and this range also cov-
ers the potential clinical doses to be used with Respimat® SMI 
(ie, 5−10 μg). A second aim of this paper was to examine 
the hazards associated with inadvertent ocular exposure to 
tiotropium. Isolated reports of acute angle-closure glaucoma 
have been documented for the nebulized short-acting anti-
cholinergic, ipratropium, administered in combination with 
the β2-agonist, salbutamol (Shah et al 1992; Hall 1994). To 
establish the potential for tiotropium to cause inadvertent 
ocular side effects, an ocular safety study (Study 2) was 
initiated in which tiotropium drops (up to 0.4 μg) were 
administered directly to one eye of healthy male volunteers. 
The highest dose was a signiﬁ  cant multiple of a percentage 
of the proposed Respimat® SMI clinical dose (ie, 5−10 μg) 
that could be inadvertently deposited in the eye.
Materials and Methods
Study design
The ﬁ  rst single-center study (Study 1; 205.112) examined the 
safety, tolerability, and pharmacokinetics of three increas-
ing doses (8, 16, and 32 μg) of tiotropium administered via 
Respimat® SMI (Boehringer Ingelheim GmbH, Ingelheim 
am Rhein, Germany). This was a randomized, double-blind 
(within-dose-groups), placebo-controlled design. The planned 
sample size was 36 volunteers, based on 3 sequential groups 
of 12 subjects each (n = 9/dose, n = 3/placebo). The second 
single-center study (Study 2; 205.138), which investigated 
the effects of inadvertent ocular exposure to tiotropium, also 
followed a randomized, double-blind (within-dose-groups), 
placebo-controlled design. The planned sample size was 48 
volunteers, based on 6 sequential groups of eight subjects 
each (n = 6/dose, n = 2/placebo). The studies were performed 
according to the Declaration of Helsinki and both protocols 
were approved by the Ethics Committee of the local Medical 
Council, Mainz, Germany. All participants provided written 
informed consent prior to participation.
Inclusion and exclusion criteria
Participants in both studies were healthy males aged between 
21 and 43 years. Subjects were excluded if the results of a 
medical examination or laboratory tests were judged by the 
clinical investigator to differ signiﬁ  cantly from normal clini-
cal values. Subjects were excluded if they had gastrointes-
tinal, hepatic, renal, respiratory, cardiovascular, metabolic, 
immunological, hormonal, psychiatric, or neurological dis-
orders, or any other condition deemed relevant to the study 
by the trial investigator. Other exclusion criteria included: 
concomitant use of any drug that might inﬂ  uence results 
of the trial; signiﬁ  cant alcohol or drug abuse; and heavy 
smoking or the inability to refrain from smoking during 
the study. For the ocular safety study, additional exclusion 
criteria included: known eye diseases, such as glaucoma; 
hyperopia (3 dioptries); contact lens use; intraocular pres-
sure 22 mm Hg; predisposition to narrow-angle glaucoma; 
and disturbed micturition.
Interventions
Following screening, subjects in Study 1 were randomized to 
receive placebo or tiotropium delivered via Respimat® SMI 
once daily for 14 days. Treatment (one inhalation) was given 
1 hour after a light breakfast by the investigating physician, 
and subjects inhaled the mist through the mouth while their 
nostrils were clamped. The inhalation doses initially planned 
(8–64 μg) were based on dose levels used in an earlier 
multiple-dose study performed with HandiHaler® (Boehringer 
Ingelheim data on ﬁ  le), and they also reﬂ  ect the potential 
clinical dose ranges to be used with Respimat® SMI (ie, 
5−10 μg). If there were no side effects with one dose tested, 
then a new group of subjects received the next higher dose 
after an interval of at least 1 week. Blinding was maintained 
at each stage. However, after completion of the tiotropium 
32 μg 14-day intervention, the incidence of anticholinergic 
adverse effects led to the replacement of the planned 64 μg 
dose level by a 16 μg dose. Hence, the different doses were 
tested consecutively in the order 8, 32, and 16 μg.International Journal of COPD 2008:3(3) 399
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Subjects in Study 2 were randomized to receive either 
placebo or a single dose of tiotropium 0.02, 0.04, 0.08, 0.16, 
0.28, or 0.40 μg applied as 2 drops (total volume 50 μl) to 1 
eye by the investigating physician. Blinding was maintained 
in each dose group. The dose range selected took into account 
(i) the dose range for inhalation that is planned for clinical 
studies (ie, 5−10 μg), (ii) that approximately 1% (worst case) 
of a dose ﬁ  red from the Respimat® SMI device directly into 
the eyes could be deposited in the area of both eyes during 
misuse of the inhaler, and (iii) was also based on animal 
models, which showed that administration of doses up to 
0.40 μg did not result in mydriasis.
Assessments
In Study 1, a general medical examination, which included 
physical and laboratory tests and an electrocardiogram 
(ECG), was carried out at screening (a maximum of 14 days 
before the ﬁ  rst inhalation [study day 1]) and within 8 days 
after the last study day. Standard laboratory tests (including 
hematological analysis, urinalysis, and serum chemistry), 
blood pressure, pulse, respiratory rate, and 12-lead ECG 
were recorded during screening, before dosing, and 25 min-
utes after medication on days 1, 7, and 14, as well as on the 
morning of day 15 and within 8 days of the ﬁ  nal inhalation. 
Salivary secretion was measured before and 35 minutes after 
drug administration on days 1, 7, and 14 using the difference 
in weight of 4 cotton rolls placed in the oral cavity before and 
after drug administration. Adverse events were monitored 
throughout the study.
Blood for determination of plasma tiotropium concen-
tration was taken before each daily inhalation, and 5 and 
20 minutes after inhalation on days 1, 7, and 14. Urine was 
collected during the intervals 0–4 hours, 4–8 hours, and 
8–24 hours after inhalation on days 1, 7, and 14. Quantitative 
determination of tiotropium in plasma and urine was achieved 
using a reverse high-pressure liquid chromatography-tandem 
mass spectrometry (HPLC-MS/MS) assay using electro-
spray ionization and multiple reaction monitoring. Airway 
resistance was evaluated before daily inhalation and 1 hour 
after inhalation on days 1, 7, and 14 using whole body 
plethysmography.
In Study 2, primary endpoints were pupillary diameter 
and pupillary reﬂ  ex, intraocular pressure, and accommo-
dation. Secondary endpoints included vital signs, 12-lead 
ECG, adverse events, and standard laboratory evaluations. 
All ocular measurements were taken at screening and on the 
treatment day (before and 1, 4, 8, and 24 hours after dosing). 
Pupillary reﬂ  ex of the treated eye was also measured 15, 30, 
and 45 minutes after dosing. Vital signs and 12-lead ECG 
measurements were taken at screening and on the treatment 
day (before treatment and after 24 hours). Adverse events 
were monitored throughout the study. Local tolerability of 
the eye – examined by assessing the presence of swelling, 
induration, calor, rubor, and pain caused by pressure – was 
included as part of the adverse-event monitoring. In addition, 
subjects were asked to report any feelings of warmth, itching, 
or spontaneous pain. The intensity of any subject-reported 
symptom was scored as being mild, moderate, or severe. All 
adverse events were monitored until they had normalized 
or had been sufﬁ  ciently characterized. A follow-up visit, 
which included medical examination, laboratory examina-
tion, 12-lead ECG, blood pressure, and pulse rate took place 
within 8 days of treatment.
Pharmacokinetics
For quantitative analysis of tiotropium in Study 1 analytes 
were extracted from plasma and urine using solid-phase and 
liquid/liquid extraction. Tiotropium was ﬁ  nally analyzed 
using HPLC-MS/MS (PE Sciex API III HPLC MS/MS sys-
tem). The chromatographic separation of the analytes was 
achieved by reverse phase liquid chromatography using a C18 
stationary phase (Kromasil 100 C18, 125 × 1.6 mm, 5 μm). An 
electrospray ion source (atmospheric pressure ionization) was 
used for ionization. The HPLC assays for plasma and urine 
samples were revalidated prior to sample analysis in the range 
3.24–108 pg/mL and 58.5–1288 pg/mL tiotropium bromide 
monohydrate, respectively. The lower limits of quantiﬁ  cation 
for the active drug (tiotropium cation) were 2.59 pg/mL in 
plasma and 11.0 pg/mL in urine. The coefﬁ  cient of varia-
tion was between 6.2% and 8.8% for plasma samples, and 
between 4.5% and 6.4% for urine samples.
Plasma concentrations were used to derive the maximum 
and predose drug plasma concentrations (Cmax and Cpre), 
the area under the tiotropium plasma concentration–time 
curve from the time of inhalation to 20 minutes postdose 
(AUC0–20min); this timeframe was identical to an earlier study 
performed with a different inhalation device (Boehringer 
Ingelheim data on ﬁ  le). Tiotropium concentrations in urine 
were used to calculate the amounts excreted unchanged in 
the urine over a deﬁ  ned time period (Aet1–t2; t1 = start of 
sampling interval, t2 = end of sampling interval).
Statistical analysis
For the safety variables, standard statistical parameters or 
frequency tables were calculated. All adverse events were 
listed and summarized in tables using the World Health International Journal of COPD 2008:3(3) 400
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Organization Adverse Reaction Terminology List (WHO-
ARTL)-preferred terms and compared between treatments.
Results
Study 1
Safety and tolerability of tiotropium administered 
via Respimat® SMI
A total of 36 healthy male subjects received treatment in 
Study 1; of these, 27 subjects received tiotropium (9 per dose 
group) and 9 subjects received placebo (3 per dose group). 
Baseline characteristics were comparable across all groups; 
the mean age of participants treated with tiotropium was 30.5 
years (range: 21−43 years), the mean height was 180 cm 
(range: 169−199 cm), and the mean body weight was 78.7 kg 
(62−102 kg). All participants were Caucasian.
No clinically relevant effects on respiratory rate and 
pulse rates, blood pressure, or ECG were observed during 
the 14 days of tiotropium treatment. No drug-related changes 
were recorded for any of the laboratory parameters measured 
(hematology, clinical chemistry, and urinalysis). One subject 
(treated with tiotropium 32 μg) discontinued the study on day 
9 for reasons unrelated to treatment. Transient dose-related 
anticholinergic adverse events were observed approximately 
1 week after treatment was initiated: 2, 5, and 14 events of 
mild-to-moderate dry mouth/throat and dry nasal mucosa 
were reported in subjects who received tiotropium 8, 16, 
and 32 μg, respectively (Table 1). No subjects who received 
placebo reported anticholinergic side effects. A marked 
reduction in unadjusted salivary ﬂ  ow was observed from 
day 1 (baseline) to day 7 in the group of subjects receiving 
tiotropium 32 μg (Figure 1); however, there was such a 
variation of mean data points on day 1 that it was difﬁ  cult 
to interpret these results. No serious adverse events were 
reported throughout the study.
Airway resistance after administration of tiotropium 
via Respimat® SMI
Airway resistance showed a slight decrease during the 
study, which was not dose-dependent and not statistically 
signiﬁ  cant. None of the healthy volunteers reported any 
respiratory symptoms.
Pharmacokinetics of tiotropium administered 
via Respimat® SMI
Tiotropium plasma concentrations increased rapidly after 
inhalation, with the highest tiotropium concentration (Cmax) 
generally observed in the blood sample collected 5 minutes 
after inhalation (Cmax = C 5min) (Figure 2). The tiotropium 
plasma concentration decreased within 20 minutes afterwards 
to about 60%–70% of the maximum value. The systemic 
exposure to tiotropium was proportional to the dose inhaled; 
for example, the C5min for tiotropium 8 μg and 32 μg was 4.23 
and 22.1 pg/mL on day 1, respectively. The C5min increased 
between day 1 and day 7 by a factor of approximately 2 
for all tiotropium doses, and between day 1 and day 14 by 
approximately 2- to 3-fold (Table 2). Thus, the increase in 
C5min from day 7 to day 14 was about 1- to 1.5-fold.
Geometric mean tiotropium plasma concentrations mea-
sured before inhalation showed a dose-related increase on 
all study days, similar to that observed for C5min (Table 2). In 
contrast to the C5min values; however, the plasma concentra-
tions before inhalation on day 14 compared with day 7 for the 
16 and 32 μg doses were still approximately 2-fold higher, 
suggesting that steady state had not been fully achieved 
within 7 days (Table 2).
AUC0–20min values showed a similar trend to that observed 
for C5min (Table 2); however, a high number of unquantiﬁ  -
able plasma concentrations for the lower doses (8 and 16 μg) 
resulted in no AUC0–20min calculations on day 1. The geometric 
mean AUC0–20min values for tiotropium 32 μg increased 3-fold 
from 4.78 pg•h/mL–1 (day 1) to 14.4 pg•h/mL–1 (day 14).
Urinary excretion of tiotropium administered via 
Respimat® SMI
The cumulative amount of urinary tiotropium excreted (in 
percent of dose) remained similar between doses on each day; 
approximately 25% of the dose was excreted at steady state 
(Figure 3). The fraction excreted in urine within 24 hours 
(Ae0–24h) increased between day 1 and day 7 by a factor of 
about 2–3, but remained similar on day 14 compared with 
Table 1 Most commonly reported adverse events following 
inhalation of tiotropium (Study 1)
 Tiotropium
8 μg
Tiotropium
16 μg
Tiotropium
32 μg
Headache 2 1 2
Dryness of nasal mucosa 1 3 5
Dryness of mouth/palate 1 2 6
Dryness of throat 3
Common cold 1 2 1
Difﬁ  culty in swallowing 3
Bitter taste 2
Herpes labialis 2
Irritation of throat 1
Irritation of conjunctiva 1 1
Tiredness 1   International Journal of COPD 2008:3(3) 401
Tolerability and ocular safety of tiotropium Respimat® SMI
day 7. The majority of the urine excretion occurred within 
the ﬁ  rst sampling interval (0–4 hours).
Study 2
Safety after tiotropium administration to the eye
A total of 48 healthy male subjects received treatment. 
The baseline characteristics were comparable across the 
six treatment groups. Overall, the mean age was 32 years 
(range: 24–44 years), the mean height was 179 cm (range: 
164−194 cm), and the mean weight was 80 kg (range: 
58–95 kg). All participants were Caucasian.
Neither the pupil diameter nor the pupillary reﬂ  ex was 
inﬂ  uenced by single doses of tiotropium up to 0.40 μg 
administered as eye drops into the eye. No clinically relevant 
ﬁ  ndings or changes in intraocular pressure were observed, 
and there was no change in accommodation in any subject. 
Swelling, induration, and erythema were not observed in 
any subject. Twenty-ﬁ  ve percent of subjects treated with 
tiotropium (9/36) and of those treated with placebo (3/12) 
reported a mild burning sensation in the treated eye. This 
sensation was transient (lasting less than 5 minutes) in all 
subjects. No subjects required any form of treatment or 
follow-up. Additionally, 2 subjects, 1 receiving tiotropium 
and 1 receiving placebo, reported a mild sensation of dry-
ness in the eye. One subject receiving tiotropium 0.40 μg 
reported a mild subjective sensation of increased intraocular 
pressure in the treated eye, although objective measurements 
of intraocular pressure in this subject showed no increase. 
The incidence of adverse effects was not dose-related. No 
clinically relevant changes in vital functions, 12-lead ECG, 
or standard laboratory parameters were observed.
Discussion
The aim of this early phase, placebo-controlled inhalation 
study was to determine the safety, tolerability, and pharma-
cokinetics of increasing doses of tiotropium administered via 
the Respimat® SMI in healthy male volunteers. In addition, 
data are presented from a separate ocular study investigating 
the safety of tiotropium when administered to the eye.
The results show that tiotropium administered via 
Respimat® SMI at increasing doses up to 32 μg was well 
tolerated. The only clinically meaningful adverse events were 
dryness of the mouth/throat and nasal mucosa. These typi-
cal anticholinergic adverse events were dose-dependent and 
led to a reduction in the ﬁ  nal dose that was evaluated, from 
the originally planned 64 μg dose to 16 μg. Anticholinergic 
events, such as those observed in this study, arise through 
the blockade of muscarinic receptors located on tissues in 
addition to the airway smooth muscle, and are a common 
occurrence with inhaled antimuscarinic therapies. Long-term 
studies with tiotropium indicate that the incidence of these 
mild anticholinergic side effects does not result in discon-
tinuation of medication in COPD patients (Casaburi et al 
2002). Although there was no positive control in this safety 
study, a subsequent crossover study, in which tiotropium 
5–10 μg Respimat® SMI was compared with tiotropium18 μg 
HandiHaler®, has shown that systemic exposure was compa-
rable for tiotropium 5 μg Respimat® SMI and tiotropium18 μg 
HandiHaler® in COPD patients (Van Noord et al 2006).
A previous study has shown that peak plasma concentra-
tions of tiotropium are measured 5 minutes after the drug 
has been inhaled via HandiHaler® (Barnes 2004; Disse 
et al 1999). Furthermore, tiotropium 18 μg inhaled via 
HandiHaler® resulted in a C5min of 14 pg/mL (approximately 
30 pM). In the current study, peak plasma concentrations 
were also achieved 5 minutes after tiotropium inhalation 
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across all dose ranges. For the tiotropium 16 μg dose, a 
C5min of 12.5 pg/mL was measured on Day 1, which suggests 
comparability with the earlier study. In this previous paper, 
the authors also suggested that tiotropium 30 pM is likely 
to correspond to a receptor occupancy of about 6%; peak 
concentrations of 9 nM (which are not achievable with inhaled 
doses) would be needed to achieve 95% receptor occupancy 
(Disse et al 1999). Such low receptor occupancy may, in part, 
explain why tiotropium is associated with a rising baseline, 
with pharmacodynamic steady state (trough FEV1 and trough 
FVC) usually being reached within two weeks. Regarding the 
achievement of pharmacokinetic steady state, trough plasma 
concentrations in the current study suggest that steady state 
had not been achieved before Day 14 for all doses tested 
despite urinary excretion remaining stable after Day 7.
In the current study, excretion of tiotropium via the urine 
was slower than has been observed in studies involving intra-
venous administration (Türck et al 2004), indicating a slower 
disposition of drug after inhalation compared with infusion. 
This was also expected, given that elimination via the kid-
ney is very rapid after an initial high load by intravenous 
infusion, whereas there might be a delay before tiotropium 
administered via inhalation is released into systemic circula-
tion. Despite a slower excretion when tiotropium is inhaled, 
previous pharmacokinetic studies show that little of the drug 
is absorbed (Barnes 2004).
The plasma concentrations of tiotropium and amount 
excreted in the urine in this study were higher than those 
observed in previous studies where similar doses of 
tiotropium were administered via a DPI (Boehringer Ingel-
heim data on ﬁ  le). Taken together, these results indicate 
that tiotropium administered via the Respimat® SMI has 
approximately a 1.5- to 2.5-fold higher bioavailability than 
similar doses administered using a dry-powder device. This 
highlights the efﬁ  ciency of Respimat® SMI in scintigraphy 
studies (Pitcairn et al 2005, Newman et al 1996); however, 
the clinical implications of this need further evaluations in 
studies involving COPD patients.
With respect to the ocular safety ﬁ  ndings, case reports of 
inadvertent administration of active compounds to the eye 
after use of inhaled anticholinergics have raised concerns 
about possible deleterious effects (Shah et al 1992; Hall 
Table 2 Pharmacokinetic parameters of tiotropium determined from plasma concentrations on days 1, 7, and 14 after once-daily inhala-
tion of tiotropium 8, 16, and 32 μg Respimat® (Study 1)
Tiotropium 8 μg (n = 9) Tiotropium 16 μg (n = 9) Tiotropium 32 μg (n = 9)
gMean % gCV gMean % gCV gMean % gCV
Day 1
C5min (pg/mL) 4.23 37.8 12.5 28.9 22.1 60.2
AUC0–20min (pg•h/mL–1) NC NC 4.78 51.4
Day 7
Cpre (pg/mL) 4.05 77.7 7.81 27.5 11.7 50.6
C5min (pg/mL) 9.51 46.8 23.2 23.7 44.2 63.1
AUC0–20min (pg•h/mL–1) 3.74 62.3 6.10 22.0 10.4 59.4
Day 14
Cpre (pg/mL) 4.75 69.0 17.9 34.5 26.7 56.4
C5min (pg/mL) 11.0 68.0 33.3 33.1 56.5 50.3
AUC0–20min (pg•h/mL–1) 3.64 63.3 10.6 17.8 14.4 53.5
Notes: NC, not calculated; n = 9 unless otherwise indicated; gMean, geometric mean; % gCV, % geometric coefﬁ  cient of variation;   AUC0–20min, area under the curve from 0 to 
20 minutes; Cpre, plasma concentration before inhalation; C5min, plasma concentration 5 minutes after inhalation.
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1994). There is one case report of acute angle-closure glau-
coma that may have been precipitated by the patient touching 
a predisposed eye with papillary dilation after inhalation of 
tiotropium (Oksuz et al 2007). In the current ocular safety 
study, no anticholinergic ocular side effects were observed 
when tiotropium was instilled into the eye at doses many 
times higher than would realistically enter the eye, even with 
inhaler misuse. This indicates that there are no obvious risks 
of anticholinergic side effects associated with inadvertent 
exposure of the eye to tiotropium at doses up to 0.40 μg. 
A previous in vitro scintigraphy study also showed that the 
potential for ocular side effects from tiotropium Respimat® 
was low; when the Respimat® soft mist was released near 
the upper face, the eye deposition was low (approximately 
0.6% of ex-valve dose, the worst-case deposition was 1%) 
(Newman et al 2007). However, physicians would be best 
advised to instruct their patients to wash their hands and 
avoid touching their eyes after use of any inhaler containing 
anticholinergics, including tiotropium.
Another important ocular safety concern relates to the 
elderly; older patients (ie, those more likely to have COPD) 
may exhibit age-related altered sensitivity to anticholiner-
gics. This could have consequences for visual acuity, which 
may impact on everyday functions such as driving. The 
Department for Transport highlights the lack of data in this 
area as a potential concern relating to older drivers (Holland 
et al 2003). Although older patients may be more sensitive 
to the effects of anticholinergics, there was no evidence of 
ocular problems in this study of healthy volunteers aged up 
to 44 years.
Conclusions
In conclusion, tiotropium delivered via the Respimat® SMI 
within a dose range of 8–32 μg once daily for 14 days was 
well tolerated in healthy volunteers. Ocular administration 
of tiotropium 0.40 μg is unlikely to result in ocular adverse 
effects such as changes in pupil diameter, pupillary reﬂ  ex, 
intraocular pressure, or accommodation. This low dose is 
equivalent to a signiﬁ  cant multiple of a percentage of the 
proposed Respimat® SMI clinical dose (ie, 5−10 μg) that 
could be inadvertently deposited in the eye.
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